Browsing Tag
Cognition Therapeutics
2 posts
Why CGTX stock could draw attention after FDA alignment on DLB psychosis
Cognition Therapeutics’ FDA alignment gives zervimesine a clearer DLB psychosis path, sharpening CGTX’s dementia drug development and stock story.
Cognition Therapeutics reports promising Phase 2 results for CT1812 in dementia with Lewy bodies
Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage pharmaceutical company focused on neurodegenerative disorder treatment, has reported highly encouraging…